ABCL
Abcellera Biologics Inc
12.80$
-2.4%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Abcellera Biologics Inc (ABCL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -34 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.5 | 1.5 | -0.8 | 0.5 | -0.8 | 26 | -3.8 | 1.7 | 110 | 162 | -5.9 | -17 | 100 | 272 | -127 | 31 | -44 | 20 | -0.1 | -20 | -42 | -29 | -29 | -8.0 | -12 | -32 | -53 | -35 | -34 | -34 | -155 | |
| 0.5 | 0.5 | 0.3 | 0.5 | 0.6 | 1.1 | 0.9 | 2.6 | 4.0 | 4.2 | 4.2 | 4.9 | 5.0 | 6.0 | 6.7 | 15 | 7.1 | 7.3 | 7.4 | 9.1 | 6.8 | 38 | 38 | -18 | 6.6 | 7.1 | 7.2 | 9.0 | 8.7 | 5.2 | 30 | |
| 0.2 | 0.2 | 0.5 | 0.1 | 1.2 | 0.6 | 1.9 | 4.6 | 5.4 | 8.5 | 7.7 | 9.0 | 12 | 12 | 12 | 13 | 15 | 16 | 16 | 16 | 17 | 18 | 17 | 15 | 15 | 14 | 14 | 13 | 12 | 12 | 51 | |
| – | – | – | 0.6 | 1.2 | 0.8 | 2.6 | 11 | 5.9 | 8.4 | 5.0 | 13 | 12 | 12 | 15 | 16 | 12 | 16 | 14 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 1.3 | 1.3 | -0.6 | 1.0 | -0.5 | 18 | -4.7 | -133 | -18 | 149 | 6.3 | -94 | -85 | 261 | -89 | 29 | -23 | 28 | 7.2 | 1.4 | -27 | -7.8 | -5.8 | -16 | 10 | -17 | -18 | -46 | -13 | -3.2 | -81 | |
| 1.7 | 1.7 | 0.1 | 0.6 | 5.6 | 3.7 | 3.9 | 1.7 | 3.6 | 37 | 8.6 | 9.4 | 14 | 31 | 13 | 12 | 15 | 27 | 20 | 14 | 24 | 20 | 19 | 16 | 11 | 13 | 8.9 | 9.8 | 3.8 | 2.1 | 25 | |
| -2.4 | -2.4 | -0.3 | -0.6 | -5.6 | -2.1 | -3.9 | -112 | -16 | -47 | -270 | -1.1 | -26 | -27 | -282 | -17 | -150 | -35 | -13 | -24 | 30 | 52 | 3.9 | 36 | 7.9 | -32 | 36 | 75 | -25 | 11 | 98 | |
| – | – | – | – | – | – | – | – | 0.2 | 1.7 | -2.8 | 1.8 | – | – | – | – | – | – | – | – | – | – | – | -1.6 | – | – | – | – | – | – | – | |
| – | – | – | 0.3 | 14 | 6.6 | -15 | 87 | -1.7 | 0.8 | 1.9 | 1.9 | 1.9 | 0.2 | -0.3 | 0.1 | 0.1 | 0.1 | 7.0 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.1 | -0.1 | 0.0 | 0.2 | 88 | 0.3 | -14 | 629 | -1.5 | -5.2 | 0.9 | 1.8 | -3.1 | 1.2 | 0.0 | 0.3 | -0.5 | 0.4 | 6.6 | 3.8 | 2.8 | 2.6 | 3.2 | 4.1 | 6.0 | -3.4 | 7.4 | 4.1 | 7.2 | 14 | 32 | |
| -1.0 | -1.0 | -1.0 | 0.1 | 81 | 24 | -22 | 503 | 92 | 107 | -275 | -17 | 70 | 245 | -417 | 15 | -194 | -13 | -7.3 | -39 | -9.7 | 25 | -22 | 30 | 2.9 | -67 | -9.3 | 45 | -53 | -7.9 | -25 | |
| -0.2 | -0.2 | -0.9 | -0.1 | -6.3 | 22 | -7.7 | 0.0 | 106 | 124 | -15 | -26 | 86 | 240 | -139 | 19 | -59 | -7.5 | -20 | -34 | -66 | -49 | -48 | -24 | -22 | -46 | -62 | -45 | -37 | -36 | -179 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.